Shares of Dr Reddys Laboratories experienced a decline of 0.67% to Rs 1228.00 during today's trading session, accompanied by high trading volume. This movement has drawn the attention of investors and market analysts, as the stock is a component of both the NIFTY 50 and NIFTY 100 indices.
The financial performance of Dr Reddys Laboratories offers insights into the company's current stock behavior. Recent financial data reveals the following trends:
Revenue
The company has demonstrated consistent revenue growth over the past year:
- Mar 2024: Rs 7,113.80 Cr
- Jun 2024: Rs 7,696.10 Cr
- Sep 2024: Rs 8,038.20 Cr
- Dec 2024: Rs 8,381.20 Cr
- Mar 2025: Rs 8,528.40 Cr
Net Profit
Net profit figures also reflect a positive trajectory:
- Mar 2024: Rs 1,306.30 Cr
- Jun 2024: Rs 1,386.50 Cr
- Sep 2024: Rs 1,335.80 Cr
- Dec 2024: Rs 1,400.00 Cr
- Mar 2025: Rs 1,581.20 Cr
Earnings Per Share (EPS)
EPS values show some fluctuation but generally indicate positive earnings:
- Mar 2024: Rs 78.66
- Jun 2024: Rs 83.61
- Sep 2024: Rs 80.45
- Dec 2024: Rs 16.97
- Mar 2025: Rs 19.12
Annual Performance
A broader look at the annual data reveals consistent growth in revenue and net profit:
- Revenue: Increased from Rs 19,047.50 Cr in 2021 to Rs 32,643.90 Cr in 2025.
- Net Profit: Rose from Rs 1,903.60 Cr in 2021 to Rs 5,703.50 Cr in 2025.
- EPS: Started at Rs 117.67 in 2021, peaked in 2024 at Rs 335.22, and stands at Rs 64.22 in 2025.
- BVPS: Rs 402.27 in 2025
- ROE: 16.85 in 2025
- Debt to Equity: 0.12 in 2025
Annual Income Statement
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 32,643 | 28,011 | 24,669 | 21,545 | 19,047 |
| Other Income | 1,097 | 894 | 1,055 | 484 | 291 |
| Total Income | 33,741 | 28,905 | 25,725 | 22,029 | 19,338 |
| Total Expenditure | 25,800 | 21,548 | 19,570 | 18,942 | 16,406 |
| EBIT | 7,940 | 7,357 | 6,154 | 3,086 | 2,932 |
| Interest | 282 | 171 | 142 | 95 | 97 |
| Tax | 1,954 | 1,623 | 1,541 | 878 | 931 |
| Net Profit | 5,703 | 5,563 | 4,470 | 2,112 | 1,903 |
Quarterly Income Statement
| Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | 8,528 | 8,381 | 8,038 | 7,696 | 7,113 |
| Other Income | 522 | 150 | 307 | 187 | 197 |
| Total Income | 9,050 | 8,531 | 8,345 | 7,883 | 7,311 |
| Total Expenditure | 6,985 | 6,579 | 6,358 | 5,946 | 5,650 |
| EBIT | 2,065 | 1,951 | 1,987 | 1,936 | 1,661 |
| Interest | 65 | 81 | 75 | 59 | 59 |
| Tax | 418 | 470 | 575 | 490 | 295 |
| Net Profit | 1,581 | 1,400 | 1,335 | 1,386 | 1,306 |
Cash Flow Statement
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 4,642 | 4,543 | 5,887 | 2,810 | 3,570 |
| Investing Activities | -5,102 | -4,028 | -4,137 | -2,638 | -2,266 |
| Financing Activities | 1,185 | -376 | -2,686 | -242 | -29 |
| Others | 22 | -5 | 28 | 73 | 11 |
| Net Cash Flow | 748 | 132 | -907 | 3 | 1,285 |
Balance Sheet
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 83 | 83 | 83 | 83 | 83 |
| Reserves & Surplus | 33,466 | 28,171 | 23,202 | 19,129 | 17,558 |
| Current Liabilities | 13,033 | 9,588 | 8,572 | 9,765 | 8,103 |
| Other Liabilities | 2,843 | 1,021 | 426 | 768 | 871 |
| Total Liabilities | 49,426 | 38,863 | 32,285 | 29,746 | 26,616 |
| Fixed Assets | 19,378 | 11,294 | 9,701 | 8,867 | 9,210 |
| Current Assets | 25,018 | 24,805 | 20,425 | 17,782 | 14,550 |
| Other Assets | 5,030 | 2,763 | 2,157 | 3,097 | 2,855 |
| Total Assets | 49,426 | 38,863 | 32,285 | 29,746 | 26,616 |
| Contingent Liabilities | 0 | 2,091 | 997 | 936 | 1,077 |
Valuation and Growth Ratios
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 64.22 | 335.22 | 271.47 | 131.57 | 117.67 |
| Diluted Eps (Rs.) | 64.13 | 334.59 | 270.90 | 131.21 | 117.34 |
| Book Value /Share (Rs.) | 402.27 | 1,693.93 | 1,397.73 | 1,154.59 | 1,060.20 |
| Dividend/Share (Rs.) | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 |
| P/E (x) | 17.82 | 3.67 | 3.41 | 6.53 | 7.68 |
| P/B (x) | 2.84 | 3.63 | 3.31 | 3.73 | 4.26 |
| EV/EBITDA (x) | 10.11 | 11.62 | 10.32 | 17.01 | 18.20 |
| P/S (x) | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 |
Moneycontrol's sentiment analysis, as of May 9, 2025, indicates a bearish outlook for the stock. Dr Reddys Laboratories' shares are currently trading lower amid high volume.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
